Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152995 · ClinicalTrials.gov registry record · Phase 2
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
A Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02152995: Active Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma, sponsored by National Cancer Institute (NCI).
NCT02152995 is a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants, above the 28-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152995, a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Metastatic Thyroid Gland Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Primary Outcome
Cohort A only. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacodynamic Study
- OTHER Iodine I 124
- RADIATION Iodine I-131
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-08-14 |
| Est. Completion | 2027-02-05 |
| Phase | Phase 2 |
What the registry record for NCT02152995 still lists
NCT02152995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, above the 28-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (21% higher).
The record links to 10 conditions, with Poorly Differentiated Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT02152995 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02152995 about?
NCT02152995 is a clinical study titled "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer". This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may hel...
What is the current status of trial NCT02152995?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2014-08-14. Estimated completion is 2027-02-05.
What conditions does trial NCT02152995 study?
This clinical trial studies the following conditions: Poorly Differentiated Thyroid Gland Carcinoma, Metastatic Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7.
What interventions are being tested in trial NCT02152995?
The interventions under investigation include: Computed Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Pharmacodynamic Study (OTHER), Iodine I 124 (OTHER), Iodine I-131 (RADIATION).
Who is sponsoring clinical trial NCT02152995?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152995 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Poorly Differentiated Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI